Adherence to lipid management guidelines is associated with lower mortality and major adverse limb events in patients undergoing revascularization for chronic limb-threatening ischemia

Journal of Vascular Surgery

Volumn 66, Issue 2, 2017, Pages 572-578

  O'Donnell, Thomas F X ^a   Deery, Sarah E ^a   Darling, Jeremy D ^a   Shean, Katie E ^a   Mittleman, Murray A ^a,b   Yee, Gabrielle N ^a   Dernbach, Matthew R ^a   Schermerhorn, Marc L ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; BIOLOGICAL MARKER;

AGED; ARTICLE; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; FEMALE; HEMODIALYSIS; HUMAN; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MORTALITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVASCULARIZATION; SMOKING; VERY ELDERLY; ADVERSE EFFECTS; AGE; BLOOD; CHI SQUARE DISTRIBUTION; CHRONIC DISEASE; CLINICAL PRACTICE; COMPLICATION; DYSLIPIDEMIAS; ENDOVASCULAR SURGERY; ISCHEMIA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERIPHERAL ARTERIAL DISEASE; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; PROTOCOL COMPLIANCE; RISK ASSESSMENT; RISK FACTOR; STANDARDS; TIME FACTOR; TREATMENT OUTCOME; TRENDS; VALIDATION STUDY; VASCULAR SURGERY;

AGE FACTORS; AGED; AGED, 80 AND OVER; BIOMARKERS; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; DYSLIPIDEMIAS; ENDOVASCULAR PROCEDURES; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISCHEMIA; LIPIDS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERIPHERAL ARTERIAL DISEASE; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR SURGICAL PROCEDURES;

EID: 85018911259     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2017.03.416     Document Type: Article

References (18)

1. Sigvant, B., Wiberg-Hedman, K., Bergqvist, D., Rolandsson, O., Andersson, B., Persson, E., et al. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vasc Surg 45 (2007), 1185–1191.
2. Diehm, C., Allenberg, J.R., Pittrow, D., Mahn, M., Tepohl, G., Haberl, R.L., et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation 120 (2009), 2053–2061.
3. Sigvant, B., Lundin, F., Wahlberg, E., Sigvant, B., Wiberg-Hedman, K., Bergqvist, D., et al. The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral arterial disease. Eur J Vasc Endovasc Surg 51 (2016), 395–403.
4. Conte, M.S., Pomposelli, F.B., Clair, D.G., Geraghty, P.J., McKinsey, J.F., Mills, J.L., et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg 61 (2015), 2S–41S.e1.
5. Abola, M.T., Bhatt, D.L., Duval, S., Cacoub, P.P., Baumgartner, I., Keo, H., et al. Fate of individuals with ischemic amputations in the REACH Registry: three-year cardiovascular and limb-related outcomes. Atherosclerosis 221 (2012), 527–535.
6. Smith, S.C., Benjamin, E.J., Bonow, R.O., Braun, L.T., Creager, M.A., Franklin, B.A., et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 124 (2011), 2458–2473.
7. Levine, G.N., Bates, E.R., Bittl, J.A., Brindis, R.G., Fihn, S.D., Fleisher, L.A., et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 68 (2016), 1082–1115.
8. Writing Committee Members, Drozda, J.P., Ferguson, T.B., Jneid, H., Krumholz, H.M., Nallamothu, B.K., et al. 2015 ACC/AHA Focused Update of Secondary Prevention Lipid Performance Measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Circ Cardiovasc Qual Outcomes 9 (2016), 68–95.
9. Stone, N.J., Robinson, J., Lichtenstein, A.H., Bairey Merz, C.N., Blum, C.B., Eckel, R.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129:Suppl 2 (2014), S1–S45.
10. Kumbhani, D.J., Steg, P.G., Cannon, C.P., Eagle, K.A., Smith, S.C., Goto, S., et al. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J 35 (2014), 2864–2872.
11. De Martino, R.R., Hoel, A.W., Beck, A.W., Eldrup-Jorgensen, J., Hallett, J.W., Upchurch, G.R., et al. Participation in the Vascular Quality Initiative is associated with improved perioperative medication use, which is associated with longer patient survival. J Vasc Surg 61 (2015), 1010–1019.
12. Subherwal, S., Patel, M.R., Kober, L., Peterson, E.D., Jones, W.S., Gislason, G.H., et al. Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains. Circulation 126 (2012), 1345–1354.
13. Cannon, C.P., Braunwald, E., McCabe, C.H., Rader, D.J., Rouleau, J.L., Belder, R., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004), 1495–1504.
14. Pedersen, T.R., Faergeman, O., Kastelein, J.J., Olsson, A.G., Tikkanen, M.J., Holme, I., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294 (2005), 2437–2445.
15. Amarenco, P., Bogousslavsky, J., Callahan, A. 3rd, Goldstein, L.B., Hennerici, M., Rudolph, A.E., et al., Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 (2006), 549–559.
16. Ford, I., Murray, H., Packard, C.J., Shepherd, J., Macfarlane, P.W., Cobbe, S.M., et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 357 (2007), 1477–1486.
17. Ho, P.M., Magid, D.J., Shetterly, S.M., Olson, K.L., Maddox, T.M., Peterson, P.N., et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 155 (2008), 772–779.
18. Heidenreich, P.A., Lewis, W.R., LaBresh, K.A., Schwamm, L.H., Fonarow, G.C., Hospital performance recognition with the Get With The Guidelines Program and mortality for acute myocardial infarction and heart failure. Am Heart J 158 (2009), 546–553.